Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. reports developments tied to its antibody discovery technology platform, partner pipeline and licensing model. The company licenses discovery research technology to pharmaceutical, biotechnology and academic partners, using engineered transgenic animals, Biological Intelligence™, computational antigen design, immunization methods, high-throughput single B-cell screening and sequencing-data mining to identify human antibody and target-binding protein candidates.
Recurring news includes quarterly financial results, partner program updates, new license agreements, milestone and royalty revenue, and technology launches such as OmniUltra™ and the xPloration® partner access program. Company updates also cover clinical and commercial progress of OmniAb-derived partnered programs, investor conference participation and corporate presentations focused on antibody discovery applications.
OmniAb (NASDAQ: OABI) reported Q1 2026 revenue of $14.4 million versus $4.2 million a year earlier and a net loss of $7.7 million ($0.06/share). The company raised full‑year 2026 revenue guidance to $28–$33 million and now expects year‑end cash of $33–$38 million.
Q1 cash costs were $12.3 million. OmniAb reported 107 active partners, 409 active programs and 32 programs in clinical development or commercialization. Management highlighted multiple partner clinical readouts due in 2026–2027.
OmniAb (NASDAQ: OABI) announced management will participate in three upcoming investor conferences: a virtual H.C. Wainwright fireside chat on May 6, a virtual Benchmark Healthcare House Call with one-on-one and small group meetings on May 28, and the Jefferies Global Healthcare Conference June 2–4 in New York, with a corporate overview on June 3 at 4:55 p.m. ET.
Management will engage with investors via virtual sessions and in-person meetings at the Jefferies event.
OmniAb (NASDAQ: OABI) will report first quarter 2026 financial results for the period ended March 31, 2026, after U.S. market close on Thursday, May 7, 2026.
The company will host a conference call and webcast that same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and business updates; replay and slides will be available via webcast.
OmniAb (NASDAQ: OABI) reported fourth-quarter and full-year 2025 results and provided 2026 guidance on March 4, 2026. Full-year 2025 revenue was $18.7M with a net loss of $64.8M and cash, equivalents and short-term investments of $54.0M at year-end.
The company exited 2025 with 107 active partners, 407 active programs and launched OmniUltra. 2026 guidance is revenue of $25–30M, operating expenses of $80–85M, cash costs of $50–55M, and expected year-end cash of $30–35M.
OmniAb (NASDAQ: OABI) will participate at the Leerink Global Healthcare Conference March 8-11, 2026, in Miami. Management will present a corporate overview on Tuesday, March 10, 2026 at 3:40 p.m. ET and will hold one-on-one investor meetings for registered attendees.
Investors should contact their Leerink Partners representative or email LeerinkEvents@Leerink.com to schedule meetings.
OmniAb (NASDAQ: OABI) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, March 4, 2026 and will host a conference call the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific. A live webcast with slides and a replay will be available.
Telephone access includes U.S. and international dial-in numbers; Conference ID is 62412.
OmniAb (NASDAQ: OABI) launched OmniUltra on December 15, 2025, described as the industry’s first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
OmniUltra generates human immune repertoires with cow-inspired ultralong CDRH3s and isolates picobodies™ (4–6 kDa), enabling antibodies and peptide therapeutics for bispecifics, CAR-T, radioligands and standalone peptides. The company presented at AET 2025 and will host a Virtual Investor Event today at 5:00 p.m. ET with slides and a replay on its investor site.
OmniAb (NASDAQ: OABI) will host a virtual investor event to unveil OmniUltra on Monday, December 15, 2025 at 5:00 p.m. ET (2:00 p.m. PT). The event is expected to run about one hour and will feature management's overview of OmniUltra, described as a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework.
Topics include the technology platform, market use and applications, and its strategic importance. A live webcast with slides and a replay will be available, and U.S. and international dial-in numbers are provided (Conference ID 44666).
OmniAb (NASDAQ: OABI) entered a technology license and services agreement with Mabtrx Biosciences, a newly formed ArrowMark–Viking joint venture, announced on November 17, 2025. The agreement covers OmniAb-derived antibody discovery programs and obligates OmniAb to provide discovery services to Mabtrx.
Under the deal OmniAb will receive revenue for services performed and is eligible for potential equity and royalties tied to discovery of novel antibodies for targets defined by Mabtrx. Management highlighted the use of OmniAb’s transgenic chicken–based technologies to support the collaboration.
OmniAb (NASDAQ: OABI) reported third quarter 2025 results on November 4, 2025: Q3 revenue $2.2M versus $4.2M year-ago and Q3 net loss $16.5M ($0.14/share). Nine-month revenue was $10.3M and nine-month net loss was $50.6M ($0.46/share).
The company ended September 30, 2025 with $59.5M in cash and equivalents after an August private placement that raised $30M (~$28M net). 2025 guidance: revenue $18–22M, operating expense $82–86M, year-end cash expected $52–56M. OmniAb reported 104 active partners, 399 active programs and 32 programs in clinical development or commercialization; OmniUltra™ launch planned for December 2025.